Research
Hormonal
Gut microbiota composition and function are altered in type 2 diabetes, characterized by reduced diversity and decreased abundance of butyrate-producing bacteria, which is associated with insulin resistance and increased diabetes risk.
People with type 2 diabetes often have less diverse gut bacteria and fewer bacteria that produce butyrate. This is a consistent finding, but it doesn't mean there's a single 'bad bacteria' to target. Focus on dietary patterns that support overall microbial diversity.
GoodSupportsHIGH confidence
Consistent features of altered GM composition in type 2 diabetes and impaired glucose tolerance/fasting glucose, found in epidemiological studies worldwide and also occurring in the metabolic syndrome, are reduced diversity and decreased abundance of bacteria that produce the short-chain fatty acid (SCFA) butyrate (Figs 1 and 2) [7–14].
Why this rating
Consistent findings across multiple epidemiological studies, though causality is complex.
Source
The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum
Mariana X. Byndloss et al. · Diabetologia · 2024
DOI 10.1007/s00125-024-06198-1
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin exerts glucose-lowering effects partly by altering gut microbiota composition to increase the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which in turn stimulate incretin hormone release.Good
- High dietary fiber intake promotes gut microbiota diversity and short-chain fatty acid generation, which decreases inflammation and supports gut barrier integrity, thereby reducing type 2 diabetes risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →